医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Recruitment of Purchase Participants for Korean Medical Device Manufacturer SDE

2015年12月14日 PM04:36
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

Located in Seongdong-gu, Seoul, Korea, the cosmetic surgery medical device manufacturer SDE Corp. officially announced their plans for technology transfer to overseas markets and for selling of the company.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151213005069/en/

SDE Corp. was established in 2014 as a venture company that manufactures and sells absorbable thread (PDO lifting thread), non-absorbable thread (PP lifting thread) and others, which are medical device consumables referred to as ‘medical sutures’.

Distinct brands of SDE Corp. include EVERKO, EASYKO, and EASY-UP. The company possesses more than four patents in Korea and China, KFDA approval, GMP certification, venture company certification, more than four cosmetic surgery patents, as well as more than four trademark registrations.

EVERKO and EASYKO enjoy very high popularity in the Korean market, and have excellent brand awareness. EASY-UP, which is another one of the brands, is an ergonomic cosmetic aid device. It is inserted into the nose and plays the role of a splint after non-incisional rhinotomy, which includes the rhinoplasty, nose filler, EVERKO, EASYKO, MISSKO, HIGHKO, etc.

According to SDE Corp. a single cosmetic surgery office located in Gangnam, Korea, purchases 10 million won worth of materials each month, and over 100 million won worth of materials a year. They also possess many customer accounts, including over 50 within Korea, in addition to medical institutions and medical device import companies overseas.

SDE Corp. has also noted, “we have determined that the cosmetic surgery market of China and South-East Asia regions, which are experiencing a wave of petite cosmetic surgery, and non-incisional cosmetic surgery, possess a wider consumer base with higher profitability than that of Korea, which has already reached saturation. Also considering only the cosmetic surgery offices and beauty shops located in each of the provinces of China, we predict over 5 billion won worth of earnings each year”. Additionally, the company indicated “Thus, for a better future and for the advancement of cosmetic surgery technology, we have decided to transfer technology overseas and to sell the company.”

Individuals of Chinese nationality or companies interested in this technology transfer and sale of the company may send an email to (sdemedi@naver.com).

View source version on businesswire.com: http://www.businesswire.com/news/home/20151213005069/en/

CONTACT

SDE Corp.
Park, so min, +82-2-547-1184
International
Marketing Manager
sdemedi@naver.com

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続